Enanta Pharmaceuticals, Inc. stock is up 10.18% since 30 days ago. The next earnings date is Feb 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 72.73% of the previous 10 December’s closed higher than November. 67% of analysts rate it a buy.
Enanta Pharmaceuticals, Inc. discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus.